Analysis of data from 622 unique enrolled patients across multiple trials showed consistent efficacy of etripamil across multiple study phases, types of trial design, and geographic regions, with ...

Background: Etripamil nasal spray is a fast-acting, calcium channel blocker in development for the conversion of paroxysmal supraventricular tachycardia (PSVT) outside of a health-care setting.

Catheter ablation as a first-line strategy for ventricular tachycardia (VT) in patients with ischemic cardiomyopathy reduces the composite endpoint of death or serious arrhythmia outcomes compared ...

When pulsed field ablation (PFA) achieved European CE mark approval in January 2021 and U. S. Food and Drug Administration (FDA) approval in December 2023, it opened up the proverbial Pandora's Box ...